CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Hoff — Advisory Committee: Roche Laboratories Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP. Dr Lenz — Clinical Trials Support: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, ImClone Systems Incorporated, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems Incorporated, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Response Genetics Inc, Sanofi-Aventis; Paid Research: Bristol-Myers Squibb Company, Celmed BioSciences Inc, Eisai Inc, Genentech BioOncology, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Taiho Pharmaceutical Co Ltd; Speakers Bureau: Eli Lilly and Company, Merck and Company Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Stock Ownership: Response Genetics Inc. Dr Hochster — Consulting Fees: Amgen Inc, Genentech BioOncology, ImClone Systems Incorporated, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Amgen Inc, Eli Lilly and Company, Genentech BioOncology, Sanofi-Aventis. Dr Hurwitz — Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Roche Laboratories Inc; Paid Research: Amgen Inc, Bristol-Myers Squibb Company, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems Incorporated, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmion Corporation, Sanofi-Aventis.

EDITOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.